Table 1:

mbp expression in larvae treated with small molecules used in primary, secondary, and validation screens

	Primary Screening (mbp:gfp)			Secondary Screening (mbp:gfp)		Validation with ISH
	average mbp:gfp PLLn score	average mbp:gfp motor nerves	n=	# increased PLLn mbp:gfp (score > 2) out of n	average mbp:gfp motor nerves	# increased PLLn mbp:gfp (score > 2) out of n	Hit for allelic series test?
control (DMSO, untreated)	0.7	1	113	0/3	1.3	0/2	n/a
forskolin pulse	1.6	0.7	22	3/3	2.3	3/3	n/a
GPCR binding
apomorphine hydrochloride	1.7	0.7	3	1/2	0.5	ND*	yes*
telmisartan	1	6	3	1/3	4	1/2	yes
naloxone hydrochloride	1.7	8	3	0/3	3.3	2/3	yes
tolazoline hydrochloride	1.7	0	3	0/3	3.4	0/3
oxelaidin citrate	1.5	0	2	1/3	1.7	0/3
norgestrel	2	0.7	3	1/3	0	0/2
cAMP elevator
rolipram	2.3	1	3	1/3	3	1/3	PDE inhibitor
steroids/hormones
triamcinolone acetonide	3	0	3	0/3	3.7	0/3
levothyroxine	2	10	1	1/3	4.7	0/2
analgesic
glafenine	1.3	4.7	3	1/3	1	0/3
other nervous system modulator
duloxetine hydrochloride	1.5	3	2	1/3	3	0/3
isaxonine	0.7	4.3	3	1/3	1	0/3
aceglutamide	1.7	1.7	3	0/2	4.5	0/2
antibacterial
ceforanide	1.3	3.3	3	1/3	1.7	0/3
betamipron	0.7	4.7	3	0/3	3.3	0/3
chlortetracycline hydrochloride	0.7	3.3	3	1/3	2.7	0/3
antifungal/antihelminthic
acedapsone	1.7	1.3	3	1/3	2.3	0/1
oxfendazole	2.7	5.7	3	1/3	2.3	0/3
undecylenic acid	1	4.3	3	1/3	2	1/2	yes
artemether	1.7	1	3	5/12**	11	0/10**
antineoplastic
azacitidine	1.3	3.3	3	0/3	4	0/3
other
sodium gluconate	1	3.3	3	0/3	3.3	0/3
tetroquinone	1.3	5.3	3	0/3	6	0/3
allantoin	1.5	2.5	2	0/3	3.3	0/1
benurestat	1	4.5	2	1/3	1	0/2

^*Apomorphine-treated larvae did not survive re-screening; however, subsequent in vivo assays are reported in Fig. 4 and in vitro assays in Fig. 5.

^**New drug stock was used (rather than Pharmakon library) in larger culture dish, see Methods